Research programme: analgesic/famotidine fixed combinations - Horizon

Drug Profile

Research programme: analgesic/famotidine fixed combinations - Horizon

Alternative Names: Aspirin/famotidine; HZN-602; HZT-602; HZT-703; Immediate-release naproxen/high-dose famotidine (HZT-602); Naproxen/famotidine

Latest Information Update: 26 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Horizon Therapeutics
  • Developer Horizon Pharma USA
  • Class
  • Mechanism of Action Cyclooxygenase inhibitors; Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 23 Mar 2012 Discontinued - Preclinical for Pain in USA (PO)
  • 01 Apr 2010 Horizon Therapeutics has merged with Nitec Pharma forming Horizon Pharma
  • 23 Jul 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top